Two Ways to Play Biotech: FBT’s Return Edge vs. IBB’s Cost Advantage
Fewer holdings, a higher fee, and a shallower drawdown set these two biotech funds apart in ways that could matter for long-term investors.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
